C=x Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding (x Is Chalcogen) Patents (Class 514/423)
  • Publication number: 20140371197
    Abstract: 4-(Azacycloalkyl)benzene-1,3-diol compounds are described corresponding to general formula (I) below: Also described, are compositions including the same, processes for preparation thereof and uses thereof in pharmaceutical or cosmetic compositions to treat pigmentary disorders.
    Type: Application
    Filed: August 29, 2014
    Publication date: December 18, 2014
    Inventors: Jean-Guy BOITEAU, Karine BOUQUET, Sandrine Talano, Corinne MILLOIS BARBUIS
  • Publication number: 20140348850
    Abstract: The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.
    Type: Application
    Filed: August 15, 2014
    Publication date: November 27, 2014
    Inventors: Edward P. Feener, Allen Clermont
  • Publication number: 20140349987
    Abstract: The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of Formula (1) and the enantiomers, diastereomers, N-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 3, 2012
    Publication date: November 27, 2014
    Inventors: Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
  • Patent number: 8895607
    Abstract: The present invention relates to a compound of Formula (I) or (II) or a salt thereof, wherein R is described herein. The compounds are novel hydroxy-proline analog inhibitors of the ASCT1 and ASCT2 neutral amino acid transporters.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: November 25, 2014
    Assignee: The University of Montana
    Inventors: Michael P. Kavanaugh, Brent Lyda, Nicholas R. Natale, Stephanie Lynn Martinelli
  • Publication number: 20140341979
    Abstract: The present invention relates, for example, to a liposome, which can be a basic liposome, a transferrin-conjugated liposome, or a pH-sensitive liposome, which encapsulates a compound that specifically inhibits the activity of a protein prenyltransferase, such as a RabGGTase and/or a GGTase I. The liposomes can be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.
    Type: Application
    Filed: July 30, 2014
    Publication date: November 20, 2014
    Inventors: Fuyuhiko Tamanoi, Jie Lu, Kohei Yoshimura, Ohyun Kwon, Hannah Fiji, Masaru Watanabe
  • Publication number: 20140335130
    Abstract: The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventors: Magali Faure, Florence Rochat, Denis Breuille, Irene Corthesy Theulaz
  • Publication number: 20140336235
    Abstract: Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.
    Type: Application
    Filed: July 30, 2014
    Publication date: November 13, 2014
    Inventors: Kyle W.H. Chan, Frank Mercurio, David I. Stirling
  • Publication number: 20140335179
    Abstract: The present invention relates to micronized crystals of atorvastatin hemi-calcium, a method for the preparation of micronized crystals of atorvastatin hemi-calcium and a pharmaceutical dosage form comprising said micronized crystals of atorvastatin hemi-calcium.
    Type: Application
    Filed: June 28, 2012
    Publication date: November 13, 2014
    Applicant: DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V.
    Inventors: Rajnish Kumar, Neeraj Tewari
  • Publication number: 20140336194
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: NOVARTIS AG
    Inventor: Shi Yin FOO
  • Patent number: 8883852
    Abstract: Provided herein are methods, for reducing, preventing, mitigating and treating damage caused by radiation. The methods comprise delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation or to mitigate apoptosis. The compounds comprise glyburide or other sulfonylurea hypoglycemic compounds or potassium channel inhibitors.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: November 11, 2014
    Assignee: University of Pittburgh—Of the Commonwealth System of Higher Education
    Inventors: Michael Epperly, Joel Greenberger, Jianfei Jiang, Valerian Kagan, John Lazo, Peter McDonald
  • Publication number: 20140329854
    Abstract: Provided are novel heterocyclic sirtuin binding agents, e.g., N-aryl substituted pyridine dicarboxamides, which are useful as sirtuin modulators. Also provided are methods of using the pyridine dicarboxamide compounds for treating sirtuin mediated disorders and conditions, such as diabetes, cancers, and obesity and diseases related to aging.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 6, 2014
    Applicant: SMB Innovation
    Inventors: Bjarne Due Larsen, Soren Andersen, Marianne Spanget Larsen
  • Publication number: 20140329815
    Abstract: The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Inventors: Carl R. ILLIG, Shelley K. Ballentine, Jinsheng Chen, Renee Louise Desjarlais, Sanath K. Meegalla, Mark Wall, Kenneth Wilson
  • Patent number: 8877799
    Abstract: The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: November 4, 2014
    Assignee: Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag
    Inventors: Andras Mravik, Imre Koehegyi, Laszlo Pongo, Balazs Volk, Gabor Nemeth, Jozsef Barkoczy, Kalman Nagy, Gyoergy Ruzsics, Judit Broda, Andras Dancso, Adrienn Keszthelyi, Jozsef Debreczeni
  • Publication number: 20140323424
    Abstract: Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are included based on the relationships of the proteins encoded by the genes in the context of particular signaling pathways and provide a diagnostically relevant nexus. Also described herein are methods of presenting the data collected by the screen, including methods of delivering interpretive comments and/or treatment guidance based on the results of the genetic screening either individually or based on the genetic composition of particular clusters of genes which may be related to each other. Importantly, drugs which modulate these genetic disturbances are described for targeted therapeutic use based upon companion diagnostic method.
    Type: Application
    Filed: July 7, 2014
    Publication date: October 30, 2014
    Inventor: Jay L. LOMBARD
  • Patent number: 8871208
    Abstract: A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: October 28, 2014
    Assignee: AbbVie Inc.
    Inventors: Peer B. Jacobson, Lisa M. Olson, Sreeinvasarao Vepachedu
  • Patent number: 8871798
    Abstract: This disclosure relates to compounds of formula I: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: October 28, 2014
    Assignee: Sanofi
    Inventors: Karl Schoenafinger, Henning Steinhagen, Bodo Scheiper, Uwe Heinelt, Volkmar Herrmann, Matthias Herrmann
  • Patent number: 8871784
    Abstract: Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation. In particular, 2(ortho)-substituted arylacetic acids or their derivatives, such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: October 28, 2014
    Assignee: Dompe'S.p.A.
    Inventors: Alessio Moriconi, Marcello Allegretti, Maria Candida Cesta, Riccardo Bertini, Cinzia Bizzarri, Francesco Colotta
  • Publication number: 20140314844
    Abstract: The present invention relates to an oral complex formulation comprising omega-3 fatty acid or its derivatives encapsulated in a hard or soft capsule containing sorbitol and sorbitan, as well as an HMG-CoA reductase inhibitor. The formulation of the present invention comprising omega-3 fatty acid encapsulated with sorbitol and sorbitan provides better prevention related materials from being formed, leading to improved long-term storage stability. The oral complex formulation of the present invention also can raise the serum HDL-cholesterol level, while reducing both LDL-cholesterol and TG levels. The oral complex formulation of the present invention is useful for treatment of hyperlipidemia.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 23, 2014
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Jin Cheul Kim, Jae Ho Kim, Eun Jin Yoon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Publication number: 20140315805
    Abstract: Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., BDNF) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation. In certain embodiments the hydrogel comprises a thiolated hyaluronan and a thiolated gelatin with an optional thiolated heparin.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 23, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stanley T. Carmichael, Andrew N. Clarkson
  • Publication number: 20140315808
    Abstract: A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Inventors: Talia WEINSTEIN, Uzi GAFTER, Zvi NEVO, Dror ROBINSON, Zoharia EVRON
  • Publication number: 20140309193
    Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2, R3, R4a and R4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.
    Type: Application
    Filed: December 5, 2012
    Publication date: October 16, 2014
    Inventors: Peter William Andrew, Rana Lonnen, Mafalda Pires Damaso, Fritz-Frieder Frickel, Simon Christopher Hirst, Mark William Davies, Daniel Hamza
  • Publication number: 20140309273
    Abstract: Provided are new fatty acid derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, e.g., as agents for the treatment of obesity and related disorders, and for improving cognition.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., AL-QUDS UNIVERSITY
    Inventors: Jehoshua KATZHENDLER, Meir SAIDIAN, Yousef NAJAJREH, Raphael MEVORACH, Elliot BERRY, Yosefa AVRAHAM
  • Publication number: 20140308244
    Abstract: Provided herein include combination therapies for the treatment of neurological inflammatory diseases, such as, for example, demyelinating autoimmune diseases, such as multiple sclerosis and neuromyelitis optica, etc. In various aspects and embodiments, the methods may include administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ACE) in combination with one or more second compounds, In one aspect, provided is a method of treating a demyelinating autoimmune disease (such as multiple sclerosis) that includes administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ACE) in combination with one or more compounds selected from the group consisting of a cytokine, a vitamin B, dimethyl fumarate (DMF, also referred to as BG-12) and fingolimod (Gilenya).
    Type: Application
    Filed: August 7, 2012
    Publication date: October 16, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lawrence Steinman, Peggy Pui-Kay Ho
  • Publication number: 20140309190
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 16, 2014
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Ma Bin, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Patent number: 8859590
    Abstract: Inhibitors of BACE1 and compositions containing them are described. Use of the inhibitors and compositions containing them to treat Alzheimer's disease are described.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: October 14, 2014
    Assignee: Purdue Research Foundation
    Inventor: Arun K. Ghosh
  • Patent number: 8859537
    Abstract: This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT4 receptor or of a functionally equivalent receptor.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: October 14, 2014
    Assignee: Centre National de la Recherche Scientifique-CNRS
    Inventor: Valerie Compan
  • Publication number: 20140303229
    Abstract: Novel skin moisturizing compositions are applied onto dry skin, particularly mild to moderately dry skin, are non-irritating and contain at least one natural moisturizing factor, butyrospermum parkii, at least one silicone, and Panthenol.
    Type: Application
    Filed: May 30, 2014
    Publication date: October 9, 2014
    Applicant: GALDERMA RESERCH & DEVELOPMENT
    Inventor: Thierry RABOUILLE
  • Publication number: 20140302150
    Abstract: The present invention relates to a pharmaceutical formulation, characterized by comprising a DPP-IV inhibitor and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
    Type: Application
    Filed: September 5, 2012
    Publication date: October 9, 2014
    Inventors: Umit Cifter, Ali Turkyilmaz, Gulay Yelken, Mehtap Saydam
  • Publication number: 20140302182
    Abstract: Embodiments of the invention generally relate to methods and supplements for increasing sex steroids and human growth hormone in a human being.
    Type: Application
    Filed: June 10, 2014
    Publication date: October 9, 2014
    Inventors: Amy L. HEATON, Mitchell K. FRIEDLANDER, Dennis GAY
  • Publication number: 20140301958
    Abstract: The purpose of this patent is to teach the methods of application and compositions of cosmetic and therapeutic products for reducing wrinkle appearance and augmenting certain compartments of the facial integument of a mammal, especially a human. These methods and compositions utilize the hypodermis-targeted release from bioadhesive oral films, pastes or patches applied to oral mucosa or teeth for the purpose of improving the appearance or health of the lips and facial skin.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 9, 2014
    Inventors: Krzysztof Bojanowski, Hui Zhao
  • Publication number: 20140302125
    Abstract: There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.
    Type: Application
    Filed: August 23, 2012
    Publication date: October 9, 2014
    Applicant: Wockhardt Ltd.
    Inventors: Mandar Madhukar Kodgule, Premchand Dalichandji Nakhat, Amit Gupta, Girish Kumar Jain
  • Patent number: 8853256
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: October 7, 2014
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Publication number: 20140296287
    Abstract: Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas 1 and 2 wherein the variables have the meaning disclosed in the specification
    Type: Application
    Filed: March 18, 2014
    Publication date: October 2, 2014
    Applicant: Allergan, Inc.
    Inventors: John E. Donello, Fabien J. Schweighoffer, Lauren M. Luhrs
  • Publication number: 20140295002
    Abstract: Embodiments of the invention generally relate to methods and supplements for improving the health of human beings.
    Type: Application
    Filed: June 10, 2014
    Publication date: October 2, 2014
    Inventors: Amy L. HEATON, Mitchell K. FRIEDLANDER, Dennis GAY
  • Publication number: 20140295003
    Abstract: A method of improving health in a canine includes administering to the canine a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland of the canines to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.
    Type: Application
    Filed: June 10, 2014
    Publication date: October 2, 2014
    Inventors: Amy L. Heaton, Mitchell K. Friedlander, Dennis Gay
  • Publication number: 20140294804
    Abstract: The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 2, 2014
    Applicant: SAINT LOUIS UNIVERSITY
    Inventor: Daniela SALVEMINI
  • Patent number: 8846616
    Abstract: A method is presented for treating an inflammatory skin disorder in a human comprising: topically applying to the skin a composition comprising alpha-melanocyte stimulating hormone (?MSH) or an ?MSH analog in an amount effective to reduce skin inflammation in the human.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: September 30, 2014
    Assignees: Florida Agricultural and Mechanical University, The Board of Trustees at the University of Arkansas
    Inventors: Mandip Singh Sachdeva, Cheryl Armstrong, Melissa A. Brown
  • Publication number: 20140288034
    Abstract: A compound having an ability to bind to an S1P receptor and represented by formula (I), a salt thereof, a solvate thereof or a prodrug thereof is useful for prevention and/or treatment of rejection of transplantation, graft-versus-host disease, autoimmune disease, allergic disease and the like: wherein ring A is a cyclic group; ring B is a cyclic group which may have substituent(s); X is a spacer having 1 to 8 atoms in its main chain, etc.; Y is a spacer having 1 to 10 atoms in its main chain, etc.; n is 0 or 1, wherein when n is 0, m is 1 and R1 is a hydrogen atom or a substituent, and wherein when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, and wherein m is 2 or more, R1s are the same or different.
    Type: Application
    Filed: June 4, 2014
    Publication date: September 25, 2014
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shinji NAKADE, Hirotaka Mizuno, Takeji ONO, Masashi Minami, Hiroshi Saga, Hiroshi Hagiya, Takaki Komiya, Hiromu Habashita, Haruto Kurata, Kazuhiro Ohtsuki, Kensuke Kusumi
  • Publication number: 20140288144
    Abstract: A compound of formula (I): R?—O-A-O—R??, in which R? and R? are a hydrogen atom or a monovalent radical of formula (IIa), or a monovalent radical of formula (IIb), it being understood that at least one of the radicals R? or R? is not a hydrogen atom and that, when none of the radicals R? and R? is a hydrogen atom, R? and R? are identical, and in which A is a divalent radical of formula (III): —CH(X1)-[C(X2)(X3)]p-CH(X4) in which X1, X2, X3 and X4 are identical or different and are either a hydrogen atom or a methyl radical or an ethyl radical, and p is an integer greater than or equal to 1 and less than or equal to 6. Also the method for preparing the compound of formula (I) and to the use thereof in cosmetics and as a drug.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 25, 2014
    Applicant: Societe D'Exploitation de Produits Pour Les Industries Chimiques Seppic
    Inventors: Sandy Dumont, Jerome Guilbot, Stephanie Garcel, Laetitia Cattuzzato
  • Publication number: 20140287040
    Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.
    Type: Application
    Filed: June 5, 2014
    Publication date: September 25, 2014
    Applicant: Novartis AG
    Inventors: Yatindra Joshi, James Kowalski, Jay Parthiban Lakshman, Alan Edward Royce, Wei-Qin Tong, Madhav Vasanthavada
  • Publication number: 20140288142
    Abstract: The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metobolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.
    Type: Application
    Filed: June 9, 2014
    Publication date: September 25, 2014
    Inventors: Nicoletta ALMIRANTE, Stefano BIONDI, Ennio ONGINI, Laura STORONI, Alessia NICOTRA
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Publication number: 20140275079
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, and R10 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Lisa A. Hasvold, John Pratt, Keith F. McDaniel, George S. Sheppard, Dachun Liu, Steven W. Elmore, Robert D. Hubbard
  • Publication number: 20140275093
    Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Application
    Filed: October 16, 2013
    Publication date: September 18, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, Sean J. Harrison, He Xu
  • Publication number: 20140274905
    Abstract: The present invention generally relates to methods of modulating Cav1.2 channels and Cav1.2 channel activators.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Duke University
    Inventors: Geoffrey S. Pitt, Adam S. Barnett, Xinhe Yin
  • Patent number: 8835480
    Abstract: The present invention relates to polyamides capable of inhibiting ARE-, GRE- and ERE-mediated gene regulation in cells. The invention also relates to methods to treat diseases related to ARE-, GRE- and ERE-mediated gene regulation.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: September 16, 2014
    Assignee: California Institute of Technology
    Inventors: Peter B. Dervan, Nicholas G. Nickols
  • Publication number: 20140256702
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • Publication number: 20140256783
    Abstract: The present invention relates to a substrate including a compound having blood anticoagulation activity and a hydrophilic polymer compound, wherein the amount of elution of the compound having blood anticoagulation activity is less than 0.6 ?g/ml, and a manufacturing method of a substrate, wherein after a compound having blood anticoagulation activity and a hydrophilic compound brought in contact with a substrate are irradiated with radiation, unreacted components are washed out.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 11, 2014
    Applicant: Toray Industries, Inc.
    Inventors: Hirokazu SAKAGUCHI, Hiroshi TAKAHASHI, Yoshiyuki UENO, Hiroyuki SUGAYA
  • Publication number: 20140249192
    Abstract: The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein R1 is selected from the group consisting of CO2R7 and CON(R7)SO2R7 wherein R1, R2, R3, R4, and R7 are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, EP3, TP and/or EP4 receptor mediated diseases or conditions.
    Type: Application
    Filed: February 12, 2014
    Publication date: September 4, 2014
    Applicant: Allergan, Inc.
    Inventors: Jose L. Martos, William R. Carling, David F. Woodward, Jenny W. Wang, Jussi J. Kangasmetsa
  • Publication number: 20140249200
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on atorvastatin therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 4, 2014
    Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Rene Braeckman, William Stirtan, Paresh Soni